Shares in consumer healthcare firm Haleon sink amid weak demand for cold and flu medicine
The FTSE 100 company said revenues rose 2.5% to £2.87bn in the three months to September 30, and it is on track for sales growth of around 2.5% in 2026.
We haven't written up this one. This Is Money has the full story — the link below goes straight to it.